Updated Jul 16, 2026
Leggett Thomas is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $147K.
Thomas Leggett is associated with Stoke Therapeutics, Inc., a biotechnology company focused on developing RNA-targeted medicines for genetic diseases. Specific details about his role or contributions to the company are not widely documented.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 37 | $32.85 | $1K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 172 | $31.79 | $5K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 2.2K | $31.28 | $68K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 922 | $33.38 | $31K |
| 2026-03-19 | STOK | Stoke Therapeutics, Inc. | S — Open-market sale | 1.3K | $32.74 | $42K |
| 2026-03-17 | STOK | Stoke Therapeutics, Inc. | M — Option exercise | 14.8K | $0.00 |
Thomas Leggett is associated with Stoke Therapeutics, Inc., a biotechnology company focused on developing RNA-targeted medicines for genetic diseases. Specific details about his role or contributions to the company are not widely documented.…
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($147K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Leggett Thomas profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.